Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $350.00 at Royal Bank Of Canada

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective cut by Royal Bank Of Canada from $445.00 to $350.00 in a research report report published on Friday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

ALNY has been the subject of a number of other research reports. Wells Fargo & Company cut their target price on shares of Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating for the company in a research note on Friday. Bank of America decreased their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Oppenheimer lowered their price target on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday. Truist Financial cut their price objective on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Finally, Needham & Company LLC reduced their price objective on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $410.72.

Alnylam Pharmaceuticals Trading Up 0.0%

Shares of Alnylam Pharmaceuticals stock opened at $205.52 on Friday. The business has a fifty day simple moving average of $287.96 and a two-hundred day simple moving average of $311.32. Alnylam Pharmaceuticals has a 1 year low of $197.81 and a 1 year high of $495.55. The company has a market capitalization of $27.44 billion, a price-to-earnings ratio of 38.20 and a beta of 0.27. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 104.81%. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the business posted ($0.44) earnings per share. The company’s revenue for the quarter was up 96.4% compared to the same quarter last year. Research analysts forecast that Alnylam Pharmaceuticals will post 7.35 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. increased its position in Alnylam Pharmaceuticals by 20.8% during the second quarter. Assenagon Asset Management S.A. now owns 155,695 shares of the biopharmaceutical company’s stock worth $46,869,000 after acquiring an additional 26,799 shares during the period. Parallel Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 65 shares during the period. Glenmede Trust Co. NA grew its position in shares of Alnylam Pharmaceuticals by 8.3% during the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 56 shares in the last quarter. Groupama Asset Managment grew its position in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock worth $12,165,000 after purchasing an additional 889 shares in the last quarter. Finally, Segall Bryant & Hamill LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $641,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and assigned a $425 price target, while JPMorgan, RBC, Oppenheimer, and Stifel maintained bullish ratings despite lowering their targets. The revised targets remain well above the current trading level. Analyst ratings and price targets
• Positive Sentiment: Alnylam reported continued strength in its transthyretin franchise, including record quarterly Amvuttra sales, and revenue increased substantially from the prior-year period. These results support the company’s underlying commercial momentum. Alnylam Q2 2026 earnings call
• Neutral Sentiment: Analysts broadly lowered their targets: JPMorgan cut its target to $375, RBC to $350, Oppenheimer to $350, Stifel to $318, Wells Fargo to $316, and Morgan Stanley to $300. Ratings range from Buy/Outperform to Equal Weight, indicating optimism about valuation but greater near-term uncertainty. Analyst price-target changes
• Negative Sentiment: Second-quarter adjusted earnings of $1.84 per share exceeded some consensus measures but missed the $2.05 Zacks estimate, while revenue of $1.29 billion fell short of the roughly $1.32 billion consensus. Alnylam Q2 earnings miss
• Negative Sentiment: The company cut its 2026 product-revenue outlook to $5.3 billion-$5.7 billion, reflecting normalization in second-line Amvuttra demand and headwinds affecting the ATTR-CM market. The guidance reduction is the primary catalyst behind the stock’s decline. Alnylam lowers 2026 outlook
• Negative Sentiment: Several law firms announced securities-fraud investigations following the results and guidance cut. These announcements may add reputational and legal overhang, although they do not establish wrongdoing. Securities-fraud investigation

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.